COMBINATIONS OF INTERFERON WITH PLATINUM COMPLEXES - SYNERGISTIC AND ANTAGONISTIC EFFECTS ON GROWTH-INHIBITION OF MCF-7 AND MDA-MB(231) BREAST-CANCER CELLS

被引:7
作者
OTTO, AM
机构
[1] Institute of Pharmacy, University of Regensburg, Regensburg
关键词
BREAST CANCER; INTERFERON; MCF-7; MDA-MB(231); PLATINUM COMPLEXES;
D O I
10.1007/BF01236385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The growth-inhibitory effects of combining interferons (IFN) with platinum(II) complexes were tested with the aim of comparing these in cultures of estrogen-receptor(ER)-negative MDA-MB(231) and ER-positive MCF-7 breast cancer cell lines. Another aim was to test whether IFN as a biological response modifier could enhance the effect of the Pt complexes in vitro in an attempt to find an explanation for their more potent antitumor effects in in vivo models. Here it is shown that in both cell lines the combinations of different IFN with all three Pt complexes generally resulted in additive growth inhibition, as calculated by the product of the fraction of surviving cells obtained with each compound alone. Moreover, in MCF-7 cells natural IFN beta (nIFN beta) combined with aqua[meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]sulfatoplatinum(II) (meso-6-Pt) resulted in synergistic inhibition. This synergy could be attributed to the estrogenic property of meso-6-Pt, since the ligand and estradiol also enhanced the inhibitory effect of nIFN beta. In contrast, the combination of recombinant IFN gamma and meso-6-Pt was antagonistic in MDA-MB(231) cells. These results show that, in spite of the similar responses of the ER-negative and ER-positive cells to each compound alone, these cells show unexpected differences in their sensitivity to combinations of IFN and the new Pt complex meso-6-Pt.
引用
收藏
页码:286 / 292
页数:7
相关论文
共 24 条
[1]   CRITERIA FOR ANALYZING INTERACTIONS BETWEEN BIOLOGICALLY-ACTIVE AGENTS [J].
BERENBAUM, MC .
ADVANCES IN CANCER RESEARCH, 1981, 35 :269-335
[2]  
BHUYAN BK, 1985, INVEST NEW DRUG, V3, P233
[3]   PREPARING NUCLEI FROM CELLS IN MONOLAYER-CULTURES SUITABLE FOR COUNTING AND FOR FOLLOWING SYNCHRONIZED CELLS THROUGH THE CELL-CYCLE [J].
BUTLER, WB .
ANALYTICAL BIOCHEMISTRY, 1984, 141 (01) :70-73
[4]  
GASTL G, 1985, CANCER RES, V45, P2957
[5]  
GOLDSTEIN D, 1989, CANCER RES, V49, P2698
[6]   BREAST CANCER-INHIBITING PROPERTIES OF LEAVING GROUP DERIVATIVES OF [1,2-BIS(2,6-DIFLUORO-3-HYDROXYPHENYL)ETHYLENEDIAMINE]PLATINUM(II) [J].
GUST, R ;
SCHONENBERGER, H .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1993, 28 (02) :117-127
[7]   RING-SUBSTITUTED [1,2-BIS(4-HYDROXYPHENYL)ETHYLENEDIAMINE]DICHLOROPLATINUM(II) COMPLEXES - COMPOUNDS WITH A SELECTIVE EFFECT ON THE HORMONE-DEPENDENT MAMMARY-CARCINOMA [J].
KARL, J ;
GUST, R ;
SPRUSS, T ;
SCHNEIDER, MR ;
SCHONENBERGER, H ;
ENGEL, J ;
WROBEL, KH ;
LUX, F ;
HAEBERLIN, ST .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (01) :72-83
[8]  
MARTH C, 1985, SERONO S PUBL RAVEN, V24, P367
[9]   A PHASE-II STUDY OF CIS-DIAMMINEDICHLOROPLATINUM-II FOR ADVANCED BREAST-CANCER 2 DOSE SCHEDULES [J].
MARTINO, S ;
SAMAL, BA ;
SINGHAKOWINTA, A ;
YOSHIDA, S ;
MACKENZIE, M ;
JAIN, J ;
VAITKEVICIUS, VK .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1984, 108 (03) :354-356
[10]   RECOMBINANT HUMAN INTERFERON-ALPHA, INTERFERON-BETA AND INTERFERON-GAMMA REDUCE THE ANTIPROLIFERATIVE ACTION OF CYTARABINE IN K562 HUMAN MYELOID-LEUKEMIA CLONOGENIC CELLS [J].
MAURER, HR ;
HASSAN, HT ;
TSIRIYOTIS, C ;
SPANDIDOS, DA .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 118 (05) :329-333